Persistence of secukinumab and ixekizumab in psoriasis

ISBN-13: 9786209386688 / Angielski / Miękka / 2025 / 60 str.

Pilar Fernández-Villacañas Fernández; Anabel Herreros Fernandez

Opis

Psoriasis is a chronic, immune-mediated inflammatory disease that requires effective and sustained treatments. Interleukin 17 inhibitors, such as secukinumab and ixekizumab, have shown high efficacy in moderate-severe psoriasis, although there may be differences in their therapeutic persistence, understood as the time that a patient maintains treatment without discontinuing it. This observational, retrospective, single-center, longitudinal, retrospective study will compare the persistence of both drugs in patients seen between January 2017 and October 2024. Data will be obtained from medical records and pharmacy records. Kaplan-Meier curves and Cox regression models will be used to analyze persistence and associated factors. The results will generate local evidence on its effectiveness in real practice, contributing to personalize therapy and improve clinical decision making.